Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
Adjuvant (ADJ) systemic therapy has transformed melanoma treatment during the past decade. There are, however, still important unanswered questions that lead to debates on the utility and place of ADJ therapy for melanoma. When ADJ trials are reported, they present a hazard ratio with a significant...
        Saved in:
      
    
          | Main Authors: | Alexander C.J. van Akkooi, Mario Mandala, Paul Nathan, Andrew Haydon, Michael Postow, Piotr Rutkowski | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Elsevier
    
        2024-12-01 | 
| Series: | EJC Skin Cancer | 
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824000053 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Freund’s adjuvant is a classic of vaccine adjuvants and the basis of experimental immunology        
                          
 by: F.V. Hladkykh
 Published: (2024-11-01)
- 
                
                    The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2        
                          
 by: Huanhuan Yan, et al.
 Published: (2025-02-01)
- 
                
                    Number needed to isolate - a new population health metric to quantify transmission reductions from isolation interventions for infectious diseases        
                          
 by: Aaron Prosser, et al.
 Published: (2024-12-01)
- 
                
                    Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs        
                          
 by: Chen Shen, et al.
 Published: (2025-01-01)
- 
                
                    Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer        
                          
 by: Sung Jun Ma, et al.
 Published: (2019-03-01)
 
       